| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_626adcf93f576ecdaf0da53ad5dfb398 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2020-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba5195cf539c59be497687e3da66f7fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6df868f284128c5fb0c7b9d25e435db |
| publicationDate |
2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020315993-A1 |
| titleOfInvention |
Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes |
| abstract |
There is herein provided pharmaceutical formulations and kits-of-parts comprising a β 2 -adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a β 3 -adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11357757-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11427539-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11648216-B2 |
| priorityDate |
2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |